Spark Therapeutics Ignites With Hot Biotech IPO TCON AVGR SHAK
Spark develops gene therapy treatments targeting rare blinding conditions, hematologic disorders and neurodegenerative diseases. In other IPOs, shares of Tracon Pharmaceuticals (NASDAQ:TCON) priced at 10, below its estimated range of 12 to 14.
Investor's Business Daily - Fri, 30 Jan 2015 10:33

IPO Preview: Spark Therapeutics
Seeking Alpha (registration) - Fri, 30 Jan 2015 05:52

IPO Report: Spark Therapeutics (ONCE)
Equities.com - Thu, 29 Jan 2015 16:56

IPO Roundup: Shake Shack Shares More Than Double Out of Gate
Spark Therapeutics' drug therapies target rare blinding diseases, hematologic disorders and neurodegenerative diseases, the company's filing said. Spark plans to use most of its proceeds to fund research and development. Must Read: 10 IPOs for 2015 ...
TheStreet.com - Fri, 30 Jan 2015 05:35

Spark Therapeutics Announces Pricing of Its Initial Public Offering
... is in a fully-enrolled pivotal Phase 3 clinical trial for the treatment of a rare blinding condition. Spark also has product candidates in development for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative ...
The Providence Journal - Fri, 30 Jan 2015 04:00

Public Release: 30-Jan-2015 Damon Runyon Cancer Research Foundation ...
He aims to characterize the genetic changes that underlie development and progression of the disease, and determine how these changes may predict sensitivity to chemotherapy. His goal is to use this information to enable more effective individualized ...
EurekAlert (press release) - Fri, 30 Jan 2015 07:11

Damon Runyon Cancer Research Foundation grants fellowship, Breakthrough ...
Phys.Org - Fri, 30 Jan 2015 07:11

Stemline Therapeutics Announces SL-701 Granted Orphan Drug Designation for ...
Orphan Drug designation is granted by the FDA's Office of Orphan Products Development for drugs that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients ...
MarketWatch - Fri, 30 Jan 2015 05:30



What You Need To Know About The Spark Therapeutics IPO
... to be Spark Therapeutics Inc (NASDAQ: ONCE) and Shake Shack (NYSE: SHAK). Spark Therapeutics is a gene therapy company focused on developing products for inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases.
Benzinga - Wed, 28 Jan 2015 11:09

IPO For Spark Therapeutics Inc. Could Be A Cure-All
Seeking Alpha (registration) - Tue, 27 Jan 2015 13:08



Biogen Idec, TIGET Launch Gene Therapy Collaboration
The vector gene therapy approach has shown promise in clinical trials for the treatment of some immune-hematologic and neurodegenerative diseases—a promise the collaboration partners hope to show in hemophilia. TIGET will receive $5 million upfront ...
Genetic Engineering & Biotechnology News - Thu, 29 Jan 2015 06:45

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce ...
Financial Mirror - Thu, 29 Jan 2015 02:30



Enzyme Inhibitor Shines in Polycythemia Vera Trial
Significantly more patients with inadequately treated polycythemia vera (PCV) achieved protocol-defined disease control with the Janus kinase (JAK) inhibitor ruxolitinib (Jakavi) than with standard therapy, a phase III trial showed. Patients treated ...
MedPage Today - Thu, 29 Jan 2015 15:48

Ruxolitinib superior to standard therapy for polycythemia vera
Healio - Wed, 28 Jan 2015 14:41

Incyte (INCY) Reports Publication of Significant Jakafi Data vs Standard ...
StreetInsider.com - Wed, 28 Jan 2015 14:16

Phase III study shows Jakavi is superior to standard therapy in rare blood ...
pharmabiz.com - Thu, 29 Jan 2015 02:30


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014